title: [Myeloproliferative neoplasms (including chronic myeloid leukemia)].
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Fukushima
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Ichinohe
authors.forename: Shinya
authors.initials: S
authors.lastname: Kimura
mesh_terms: D001549:Benzamides; D000069439:Dasatinib; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D058990:Molecular Targeted Therapy; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D013844:Thiazoles / Q000627:therapeutic use; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics
chemical_list: D001549:Benzamides; C479818:FIP1L1 protein, human; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D020796:Receptor, Platelet-Derived Growth Factor alpha; D053614:Janus Kinase 2; C498826:nilotinib; D000069439:Dasatinib